Helsinn’s anamorelin HCI has been accepted for marketing authorisation application (MAA) review by the European Medicines Agency (EMA)
Helsinn’s anamorelin HCI has been accepted for review by the EMA
Anamorelin HCI is an orally active selective ghrelin receptor agonist. Ghrelin is an endogenous peptide primarily secreted by the stomach.
Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, lean body mass, appetite and metabolism.
Anamorelin HCI is under development by Helsinn for the treatment of anorexia, cachexia or unintended weight loss in non-small cell lung cancer (NSCLC) patients.
Riccardo Braglia, chief executive officer of Helsinn Group said: “With this EMA submission, we are one step closer to bringing this new and potentially effective treatment to market, meaning that the quality of life for patients with non-small cell lung cancer who suffer from anorexia, cachexia, could soon improve.
“Anamorelin is part of our pipeline of products dedicated to cancer supportive care, all of which address areas of significant unmet medical need.”
Anamorelin HCI is an investigational agent that has not yet been approved by any regulatory authority.